CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks

Wednesday, June 9, 2010 - 15:40 in Health & Medicine

DURHAM, N.C., June 9 — CoLucid Pharmaceuticals, Inc., (“CoLucid”), an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced...

Read the whole article on Science Blog

More from Science Blog

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net